WO2002015916A1

WO2002015916A1 - Use of dihydroboswellic acids or hydrogenated extracts of boswellia for prophylactic and/or therapeutic treatment

Info

Publication number: WO2002015916A1
Application number: PCT/EP2001/009315
Authority: WO
Inventors: Thomas Gerke; Stefan Müllner; Wolfgang Denuell
Original assignee: Henkel Kommanditgesellschaft Auf Aktien
Priority date: 2000-08-22
Filing date: 2001-08-11
Publication date: 2002-02-28
Also published as: DE10041217A1; AU2001285885A1

Abstract

The invention relates to dihydroboswellic acids and the physiologically tolerable salts and derivatives thereof, the physiologically tolerable salts of said derivatives and hydrogenated extracts of boswellia. The invention also relates to a method for the production of the same and the use of dihydroboswellic acids, physiologically tolerable salts, and derivatives thereof, the physiologically tolerable salts of said derivatives or hydrogenated extracts of boswellia for prophylactic and/or therapeutic treatment of undesired physical or mental conditions in humans or animals.

Description

Patent application H 4773

USE OF DIHYDROBOSWELLIA ACIDS OR HYDRATED EXTRACTS FROM BOSWELLIA FOR PROPHYLACTIC AND / OR THERAPEUTIC TREATMENT

Description:

The present invention relates to dihydroboswellic acids and their physiologically acceptable salts, derivatives and salts of derivatives and hydrogenated extracts from Boswellia, processes for their preparation and the use of dihydroboswellic acids, physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia for prophylactic purposes and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals.

Gum resin from Boswellia serrata (Indian frankincense) is known for its aromatic scent as a therapeutic agent in aromatherapy. In this context, it serves in particular to restore the mental balance, especially for depression and mood disorders. From Dt Ärztebl 1998; 95: A-30-31 [Issue 1-2] is known to use gum resin from Boswellia serrata Roxb in India as a traditional medicine from Ayurvedic medicine for a number of inflammatory diseases, such as rheumatoid arthritis, osteoarthritis and cervical spondylosis , is used. The main components of this gum resin are boswellic acids and other compounds such as essential oils, terpinols, arabinose, xylose, galactose, uronic acids, b-sitosterol and phlobaphene. Tablets made from extracts of this resin are used in India for the treatment of chronic polyarthritic tis manufactured under the trade names Sallaki ^® and H15 ^® . Boswellia extracts and boswellic acids have anti-inflammatory properties, as has been demonstrated in a large number of animal models. Boswellic acids are also components of the gum resin from Boswellia carterii Birdw., Which was listed as an olibanum in German pharmacopoeias (supplementary volumes DAB 6 and DAB 1). The previously known pharmacological effects of olibanum are described as anti-inflammatory, analgesic, immunosuppressive, hepatoprotective and antimicrobial. Boswellic acids have been shown to have similar properties.

Inflammation is characterized by redness, warmth, swelling, pain and impaired organ function. These symptoms are caused by a number of inflammatory mediators. The current treatment of inflammation occurs either through compounds that inhibit prostaglandin synthesis, but not leukotriene synthesis; they are called non-steroidal anti-inflammatory drugs / anti-rheumatic drugs; or by glucocorticoids that inhibit the formation of prostaglandins and leukotrienes. However, both categories of these anti-inflammatory drugs are associated with a whole series of sometimes serious side effects. This applies in particular to the chronic use of glucocorticoids.

Prostaglandins and leukotrienes are formed via the so-called arachidonic acid cascade. A concentration-dependent inhibitory effect of boswellic acids, in particular acetyl-boswellic acids, on the formation of leukotrienes and other 5-lipoxygenase products is known from the abovementioned publication. Among the boswellic acids, the acetyl-11keto-boswe Ilic acid was the strongest in vitro (IC50 = 1.5 μM). Further investigations into the possible effects of an acetyl-boswellic acid mixture on cyclooxygenase or 12-lipoxygenase showed that it was unable to influence prostaglandin synthesis or 12-lipoxygenase activity. The results indicated that these natural products only inhibit the formation of leukotrienes in the arachidonic acid cascade. Further studies on this topic showed that it is a non-competitive and reversible effect on this enzyme.

In addition to the inhibitory effect on leukotriene biosynthesis, it was described in the above-mentioned publication that boswellic acids inhibit the proliferation of tumor cells such as HL60 and CCRF-CEM gliobastoma cells and melanoma cell in vitro, but in considerably higher concentrations.

In addition to the inhibition of cell proliferation, induction of apoptosis and inhibition of topoisomerase I was observed in HL60 cells.

Leukotrienes have a number of effects, most of which are involved in inflammation. However, broncho-constrictive effects have also been described. There are a large number of chronic inflammatory diseases in which an increased leukotriene production is considered to be partly responsible for the maintenance of the chronic inflammation. These diseases include ulcerative colitis, Crohn's disease, bronchial asthma, rheumatoid arthritis and others.

DE-A-42 01 903 and EP-A-0 552 657 disclose the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for prophylaxis and / or control of inflammatory processes that are caused by increased leukotriene formation, are known in human or veterinary medicine.

WO 97/07796 describes the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for the prophylaxis and / or combating of diseases caused by increased leucocyte elastase - or piasmin activity are caused or which can be treated by inhibition of normal leukocyte elastase or piasmin activity, are known in human or veterinary medicine. The resin from boswellia species, boswellic acid and their derivatives are only slightly toxic, but side effects (gastrointestinal complaints, allergic reactions) have also been described when used as directed (Dt Ärztebl 1998; 95: A-30-31 [Issue 1-2]) ).

The object of the present invention is to provide a substance which can be used for the preventive or therapeutic treatment of undesirable physical or mental conditions, in particular the abovementioned diseases, while avoiding as far as possible the disadvantages known from the prior art.

Surprisingly, it was found that dihydroboswellic acids or hydrogenated extracts from Boswellia can be used prophylactically and / or therapeutically in a similar manner to the known boswellic acids and boswellia extracts. This finding was particularly unexpected because the hydrogenation of the single carbon-carbon double bond in the basic structure common to all boswellic acids significantly changed the spatial structure of the molecule, so that it could not be assumed that the biochemical activity (inhibitory effect) would be retained.

Mutually independent objects of the present invention are therefore dihydroboswellic acids, physiologically acceptable salts of dihydroboswellic acids and hydrogenated extracts from Boswellia.

Another object of the present invention is the use of dihydroboswellic acids, physiologically acceptable salts of dihydroboswellic acids or hydrogenated extracts from Boswellia for the prophylactic and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals.

In the context of the present invention, “dihydroboswellic acids” includes compounds of the formulas A and B, in particular those with the following led substituents understood:

R = H 11-keto-ß-dihydroboswellic acid R = acetyl acetyl-11-keto-ß-dihydroboswellic acid R = formyl formyl-11-keto-ß-dihydroboswellic acid

R = H: α-dihydroboswellic acid

R = acetyl: acetyl-α-dihydroboswellic acid

R = formyl: formyl-α-dihydroboswellic acid

The sodium, potassium, ammonium or calcium salts can be used as physiologically acceptable salts of dihydroboswellic acid. As derivatives of dihydroboswellic acid, lower alkyl esters obtained by esterifying the carboxyl group with a C 1 -C 6 -alcohol, preferably the methyl ester, or esters obtained by esterifying the hydroxyl group obtained with a physiologically compatible carboxylic acid can be used. Preferred derivatives are β-dihydroboswellic acid acetate, β-dihydroboswellic acid formate, β-dihydroboswellic acid methyl ester, acetyl-β-dihydroboswellic acid, acetyl-11-keto-β-dihydroboswellic acid and 11-keto-β-dihydroboswellic acid. Plants which contain boswellic acid (syn .: boswellic acid) and from which extracts can be obtained for the subsequent hydrogenation are, for example: Boswellia (serrata, papyrifera, frereana, carteri, thurifera, glabra, bhaw-dajiana, oblongata, socotrana and other representatives of these Family).

The compounds which can be used according to the invention can be obtained by hydrogenation, preferably by catalytic hydrogenation of Boswellia resin or Boswellic acids (one or different) or physiologically acceptable salts, derivatives or salts of the derivatives of these acids.

The present invention therefore furthermore relates to a process for the preparation of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia, using Boswellia resin or Boswellic acids (one or different) or physiologically acceptable salts, derivatives or Dissolves salts of the derivatives of these acids in a suitable solvent and hydrogenates the dissolved resin or the dissolved acids, salts, derivatives or salts of the derivatives in the presence of a hydrogenation catalyst. Suitable solvents are, for example, alkanols, in particular ethanol, and cyclohexane.

The hydrogenation is carried out in a manner known to those skilled in the art, preferably in such a way that the carbon-carbon double bond of the boswellic acid backbone is selectively hydrogenated.

The hydrogenation can take place under heterogeneous or under homogeneous catalysis. In the case of heterogeneous catalysis, there is a catalyst which is insoluble in the reaction medium and on the surface of which the actual catalysis is brought about by adsorption and desorption equilibria of the compound to be hydrogenated and the hydrogen. Suitable catalysts are noble metals such as Pt, Pd and Rh or transition metals such as Mo, W, Cr, but especially Fe, Co and. Ni, either individually or in a mixture or to increase the activity and stability on supports such as activated carbon, aluminum oxide or diatomaceous earth. Raney nickel, Pd bound to activated carbon, metallic Pt and platinum and zinc oxide can be used in particular.

In homogeneous catalysis, catalysts are soluble in the reaction medium. Suitable catalysts for homogeneous catalysis are transition metal complexes, for example the well-known Wilkinson catalyst [chlorotris (triphenylphosphine) rhodium].

Preferably the hydrogenation is carried out with supported catalysts in a heterogeneous system, e.g. in a fixed bed or in a fluidized bed or in the so-called trickle phase.

The hydrogenation conditions can be varied in a known manner by the person skilled in the art. The hydrogenation temperature can be in the range from approximately 0 ° C. to approximately 275 ° C., in particular in the range from approximately 80 ° C. to approximately 120 ° C. The pressure can be in the range from normal pressure up to about 300 bar, preferably in the range from about 150 bar to about 250 bar.

The undesirable physical or mental conditions to be treated in the context of the use according to the invention are preferably selected from somatic, psychosomatic and psychological disorders in humans or animals; especially among inflammatory processes caused by increased leukotriene formation and especially under inflammatory joint diseases, epidermal lesions (psoriasis), allergic and chronic asthma, endotoxin shock, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or chronic hepatitis.

Further undesirable physical conditions to be treated in the context of the use according to the invention are preferably selected from those which are caused by increased leukocyte elastase or piasmin activity or which can be treated by inhibiting normal leukocyte elastase or piasmin activity; especially those with pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (cystic fibrosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, which are caused by increased leukocyte elastase activity, and tumors and tumor metastases, which are caused by increased piasmina.

The use according to the invention of dihydroboswellic acids, physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia is preferably carried out intraperitoneally, orally, buccally, rectally, intramuscularly, topically, subcutaneously, by inhalation, intra-articularly or intravenously.

In particular, the use according to the invention takes the form of tablets, dragées, capsules, solutions, emulsions, ointments, creams, inhalation preparations, aerosols or suppositories.

Another object of the present invention is the use of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of derivatives or hydrogenated extracts from Boswellia for the manufacture of a medicament for the prophylactic and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals, especially for the treatment of the conditions and diseases mentioned above. The use according to the invention of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia for the treatment of undesirable conditions or for the production of a medicament can take place together with other chemically pure medicinal substances and / or herbal medicinal products. Suitable medicinal substances or medicinal products are listed in DE-A-42 01 903, to which reference is hereby made in full.

Examples of such chemically pure drugs are:

Broncholytics and anti-asthmatics, sympathomimetics:

Carbuterol-HCI,, Clenbuterol-HCI, Fenoterol-HBr, Isoetarin-HCI, Orciprenalin-sulfate, Pirbuterol-HCI, Procaterol-HCI, Reproterol-HCI, Sabutamol sulfate, Terbutalin sulfate, Tulobuterol-HCI. Antipsoriatics, non-steroidal anti-inflammatory drugs: salicylic acid and derivatives.

vitamins:

Folic acid, vitamin E, vitamin B12, vitamin A.

Various:

Cadmium sulfide, benzalkonium chloride, sodium bituminosulfonate, ammoidin, allantoin, methotrexate, paraffin, dioxolone, dithranol, fumaric acid,

Undecylenic acid, polyoxyethylene lauryl ether sulfate, etretinate, zinc oxide, urea, lactic acid.

Nonsteroidal anti-inflammatory drugs: pyrazole derivatives: Azapropazon, Bumadizon, Famprofazon, Mofebutazon, Nifenazon, Oxyphenbutazon, Phenylbutazon, Pyrazinobutazon.

Acrylic acetic acid derivatives and indole derivatives: acemetacin, bufexamac, diclofenac, indomethacin, lonazolac, proglumetacin, tolmetin.

Anthranilic acid derivatives: flufenamic acid, mefenamic acid, niflumic acid.

Aryl propionic acid derivatives:

Carprofen, fenoprofen, fenbufen, fluorobiprofen, ibuprofen, ketoprofen,

Naproxen, piroxicam, pirprofen, tiaprofenic acid.

Oxicame: tenoxicam

other:

Benzydamine, benfotiamine, chloroquine, hydroxychloroquine, auranofin, (ID-glucosylthio) gold, aurothiomalate (= gold keratinate), tetrachlorogold (III) acid, D-penicillamine, hyaluronidase, nabumetone, etofenamate, ademetionin, seriopeptilchloride, seriopeptilase, serrapeptase, serrapeptase Methotrexate, glucosamine sulfate, penicillin, bee venom preparation, sulfur, oxaceprol, orgotein, sulfasalazzine (= salazosulfapyridine).

The dosage and duration of use of the dihydroboswellic acids, physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia to be used according to the invention and the preparation of the medicaments containing them are carried out essentially as in DE-A-42 01 903 and WO 97 / 07796 for non-hydrogenated boswellic acid and its deri vate described. Reference is therefore made in full to these two disclosures.

Dihydroboswellic acid and hydrogenated extracts from Boswellia have an odor that is clearly distinguishable from that of their unhydrogenated starting compounds, but this is similarly aromatic and pleasant as that of the unhydrogenated starting compounds.

Therefore dihydroboswellic acid and hydrogenated extracts from Boswellia can also be used for aromatherapy. In addition, because of their pleasant smell and the anti-inflammatory effect described above, they can be used as valuable components of cosmetics and personal care products.

Another object of the present invention is therefore the use of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia in or for the production of hand washing detergents, hand dishwashing detergents, cosmetics or personal care products.

The present invention furthermore relates to medicaments, personal care products, cosmetics, hand washing detergents and dishwashing detergents which contain dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia.

The cosmetics and personal care products according to the invention, such as, for example, hair shampoos, hair lotions, foam baths, shower baths, creams, gels, lotions, alcoholic and aqueous / alcoholic solutions, emulsions, wax / fat masses, stick preparations, powders or ointments, can be used as auxiliaries and additives, mild surfactants, Oil bodies, emulsifiers, superfatting agents, pearlescent waxes, consistency enhancers, thickeners, polymers, silicone compounds, fats, waxes, stabilizers, biogenic agents, deodorants, antiperspirants rantien, anti-dandruff agents, film formers, swelling agents, UV light protection factors, antioxidants, hydrotropes, preservatives, insect repellents, self-tanners, solubilizers, perfume oils, dyes and the like contain.

Typical examples of suitable mild, i.e. surfactants which are particularly compatible with the skin are fatty alcohol polyglycol ether sulfates, monoglyceride sulfates, mono- and / or dialkyl sulfosuccinates, fatty acid isethionates, fatty acid sarcosinates, fatty acid tauids, fatty acid glutamates, α-olefin sulfonates, ether carboxylic acids, alkyl oligogluamide amides, fatty acids / fatty acids / protein amides, fatty acids / fatty acid amides and fatty acids, fatty acids / fatty acid amides / fatty acids, fatty acids / fatty acid fatty acids, and / or fatty acid fatty acids, fatty acids / fatty acid fatty acids, fatty acid fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids, fatty acids wheat proteins.

Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10 carbon atoms, esters of linear C ₆ -C ₂₂ fatty acids with linear C6-C ₂₂ fatty alcohols, esters of branched C ₆ -Cι ₃ - are, for example, oil bodies. Carboxylic acids with linear C ₆ -C ₂₂ fatty alcohols, such as, for example, myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl paletate, cetyl paletate - did stearylstearate, Stearylisostearat, stearyl, stearyl, Stearyleru- cat, isostearyl, isostearyl, Isostearylstearat, isostearyl isostearate, Isostearyloleat, isostearyl behenate, Isostearyloleat, oleyl, oleyl palmitate, oleyl stearate, oleyl isostearate, oleate, Oleylbehenat, oleyl, Behenylmy- ristat, behenyl, behenyl , Behenyl isostearate, behenyl oleate, behenyl behenate, behenyl erucate, erucyl myristate, erucyl palmitate, erucyl stearate, erucyl isostearate, erucyl oleate, erucyl behenate and erucylerucate.

In addition, esters of linear C ₆ -C ₂₂ fatty acids with branched are suitable

Alcohols, especially 2-ethylhexanol, esters of hydroxycarboxylic acids with linear or branched C ₆ -C ₂₂ fatty alcohols, especially dioctyl malates,

Esters of linear and / or branched fatty acids with polyhydric alcohol len (such as propylene glycol, dimer diol or trimer triol) and / or Guerbet alcohols, triglycerides based on Cβ-Cio fatty acids, liquid mono- / di- / triglyceride mixtures based on C ₆ -C ₈ fatty acids, esters of C6-C22 - Fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids, especially benzoic acid, esters of C ₂ -Ci ₂ dicarboxylic acids with linear or branched alcohols with 1 to 22 carbon atoms or polyols with 2 to 10 carbon atoms and 2 to 6 hydroxyl groups, vegetable oils, branched primary Alcohols, substituted cyclohexanes, linear and branched C ₆ -C ₂₂ fatty alcohol carbonates, Guerbet carbonates, esters of benzoic acid with linear and / or branched C ₆ -C ₂₂ alcohols (e.g. Finsolv ^® TN), linear or branched, symmetrical or asymmetrical dialkyl ethers 6 to 22 carbon atoms per alkyl group, ring opening products of epoxidized fatty acid esters with polyols, silicone oils and / or aliphatic or naphthenic Hydrocarbons such as B. squalane, squalene or dialkylcyclohexanes.

Examples of suitable emulsifiers are nonionic surfactants from at least one of the following groups:

(1) Adducts of 2 to 30 moles of ethylene oxide and / or 0 to 5 moles of propylene oxide with linear fatty alcohols with 8 to 22 carbon atoms, with fatty acids with

12 to 22 carbon atoms, on alkylphenols with 8 to 15 carbon atoms in the alkyl group and alkylamines with 8 to 22 carbon atoms in the alkyl radical;

(2) Ci2 / i8 fatty acid monoesters and diesters of adducts of 1 to 30 moles of ethylene oxide with glycerol; (3) glycerol monoesters and diesters and sorbitan monoesters and diesters of saturated and unsaturated fatty acids having 6 to 22 carbon atoms and their ethylene oxide addition products;

(4) alkyl and / or alkenyl mono- and oligoglycosides with 8 to 22 carbon atoms in the alk (en) yl radical and their ethoxylated analogs; (5) adducts of 15 to 60 moles of ethylene oxide with castor oil and / or hardened castor oil; (6) polyol and especially polyglycerol esters;

(7) adducts of 2 to 15 moles of ethylene oxide with castor oil and / or hardened castor oil;

(8) _{partial esters} based on linear, branched, unsaturated or saturated C _6/22 fatty acids, ricinoleic acid and 12-hydroxystearic acid and glycerol,

Polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) and polyglucosides (e.g. cellulose);

(9) mono-, di- and trialkyl phosphates and mono-, di- and / or tri-PEG-alkyl phosphates and their salts;

(10) wool wax alcohols;

(11) polysiloxane-polyalkyl-polyether copolymers or corresponding derivatives;

(12) mixed esters of pentaerythritol, fatty acids, citric acid and fatty alcohol according to DE 1165574 PS and / or mixed esters of fatty acids with 6 to 22 carbon atoms, methyl glucose and polyols, preferably glycerol or polyglycerol,

(13) polyalkylene glycols and

(14) Glycerol carbonate.

The adducts of ethylene oxide and / or of propylene oxide with fatty alcohols, fatty acids, alkylphenols, glycerol mono- and diesters, and sorbitan mono- and diesters with fatty acids or with castor oil are known, commercially available products.

These are homolog mixtures whose average degree of alkoxylation corresponds to the ratio of the amounts of ethylene oxide and / or propylene oxide and substrate with which the addition reaction is carried out. ₁₂ C _/ i ₈ fatty acid monoesters and diesters of addition products of ethylene oxide onto glycerol are known from DE 2024051 as refatting agents for cosmetic preparations. Alkyl and / or alkenyl mono- and oligoglycosides, their preparation and their use are known from the prior art. They are produced in particular by reacting glucose or oligosaccharides with primary alcohols with 8 to 18 carbon atoms. With regard to the glycoside residue, both monoglycosides in which a cyclic sugar residue is glycosidically bonded to the fatty alcohol and oligomeric glycosides with a degree of oligomerization of up to about 8 are suitable. The degree of oligomerization is a statistical mean value which is based on a homolog distribution customary for such technical products.

Typical examples of suitable polyglycerol esters are polyglyceryl-2 dipolyhydroxystearate (Dehymuls ^® PGPH), polyglycerol-3-diisostearate (Lameform ^® TGI), polyglyceryl-4 isostearate (Isolan ^® Gl 34), polyglyceryl-3 oleates, diisostearoyl polyglyceryl 3 diisostearates (Isolan ^® PDI), polyglyceryl-3 methyl glucose distearate (Tego Care ^® 450), polyglyceryl-3 beeswax (Cera Bellina ^® ), polyglyceryl-4 caprate (polyglycerol caprate T2010 / 90), polyglyceryl-3 cetyl ether ( Chimexane ^® NL), Polyglyceryl-3 Distearate (Cremophor ^® GS 32) and Polyglyceryl Polyricinoleate (Admul ^® WOL 1403), Polyglyceryl Dimerate Isostearate and their mixtures.

Zwitterionic surfactants can also be used as emulsifiers. Zwitterionic surfactants are surface-active compounds that contain at least one quaternary ammonium group and at least one carboxylate and one sulfonate group in the molecule. Particularly suitable zwitterionic surfactants are the so-called betaines such as the N-alkyl-N, N-dimethylammonium glycinate, for example the coconut alkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinate, for example the coconut acylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxylm -hydroxyethylimidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethyl- carboxymethylglycinat. The fatty acid amide derivative known under the CTFA name Cocamidopropyl Betaine is particularly preferred. Suitable emulsifiers are ampholytic surfactants. Ampholytic surfactants are surface-active compounds which, in addition to a Cs _/ is alkyl or acyl group, contain at least one free amino group and at least one -COOH or -SOsH group in the molecule and are capable of forming internal salts. Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each about 8 to 18 carbon atoms in the alkyl group. Particularly preferred ampholytic surfactants are N-coconut alkyl aminopropionate, coconut acylaminoethyl aminopropionate and C12 / 18 acyl sarcosine. In addition to the ampholytic emulsifiers, quaternary emulsifiers are also suitable, those of the esterquat type, preferably methyl-quaternized difatty acid triethanolamine ester salts, being particularly preferred.

Substances such as, for example, lanolin and lecithin and polyethoxylated or acylated lanolin and lecithin derivatives, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides can be used as superfatting agents, the latter simultaneously serving as foam stabilizers.

Pearlescent waxes that can be used are, for example: alkylene glycol esters, especially ethylene glycol distearate; Fatty acid alkanolamides, especially coconut fatty acid diethanolamide; Partial glycerides, especially stearic acid monoglyceride; Esters of polyvalent, optionally hydroxy-substituted carboxylic acids with fatty alcohols having 6 to 22 carbon atoms, especially long-chain esters of tartaric acid; Fatty substances, such as, for example, fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates, which have a total of at least 24 carbon atoms, especially lauron and distearyl ether; Fatty acids such as stearic acid, hydroxystearic acid or behenic acid, ring opening products of olefin epoxides with 12 to 22 carbon atoms with fatty alcohols with 12 to 22 carbon atoms and / or polyols with 2 to 15 carbon atoms and 2 to 10 hydroxyl groups and mixtures thereof.

The main consistency agents are fatty alcohols or hydroxy fatty alcohols with 12 to 22 and preferably 16 to 18 carbon atoms and, in addition, partial glycerides, fatty acids or hydroxy fatty acids. A combination of these substances with alkyl oligoglucosides and / or fatty acid N-methylglucamides of the same chain length and / or polyglycerol poly-12-hydroxystearates is preferred.

Suitable thickeners are, for example, Aerosil types (hydrophilic silicas), polysaccharides, in particular xanthan gum, guar guar, agar agar, alginates and tyloses, carboxymethyl cellulose and hydroxyethyl cellulose, and also higher molecular weight polyethylene glycol mono- and diesters of fatty acids, polyacrylates (eg carbopols) ^® from Goodrich or Synthalene ^® from Sigma), polyacrylamides, polyvinyl alcohol and polyvinylpyrrolidone, surfactants such as ethoxylated fatty acid glycerides, esters of fatty acids with polyols such as pentaerythritol or trimethylolpropane, fatty alcohol ethoxylates with a narrow homolog distribution or alkyl oligoglucosides and electrolytes such as sodium chloride and ammonium chloride.

Suitable cationic polymers are, for example, cationic cellulose derivatives, such as a quaternized hydroxyethyl cellulose, which is available under the name Polymer JR 400® from Amerchol, cationic starch, copolymers of diallylammonium salts and acrylamides, quaternized vinylpyrrolidone / vinylimidazole polymers , such as Luviquat® (BASF), condensation products of polyglycols and amines, quaternized collagen polypeptides, such as, for example, lauryldimonium hydroxypropyl hydrolyzed collagen (Lamequat®L / Grünau), quaternized wheat polypeptides, polyethyleneimine, cationic silicone polymers, such as, for example, amidomethicones and copolymers of the adicates Dimethylaminohydroxypropyldiethylenetriamine (Cartaretine® / Sandoz), copolymers of acrylic acid with dimethyldiallylammonium chloride (Merquat® 550 / Chemviron), polyaminopolyamides, as described, for example, in FR 2252840 A and their crosslinked water-soluble polymers, cationic chitin derivatives such as, for example, quaternized chitosin, optionally distributed, optionally Condensation products from dihaloalkylene, such as, for example, dibromobutane with bisdialkylamines, such as, for example, bis-dimethylamino-1,3-propane, cationic guar gum, such as, for example, Jaguar® CBS, Jaguar® C-17, Jaguar® C-16 from Celanesis, quaternized ammonium salt polymers, such as Mirapol® A-15, Mirapol® AD-1, Mirapol® AZ-1 from Miranol.

Anionic, zwitterionic, amphoteric and nonionic polymers include, for example, vinyl acetate / crotonic acid copolymers, vinyl pyrrolidone / vinyl acrylate copolymers, vinyl acetate / butyl maleate / isobomylacrylate copolymers, methyl vinyl ether / maleic anhydride copolymers and their polyols and uncrosslinked polyols and their esters , Acrylamidopro- pyltrimethylammoniumchlorid / acrylate copolymers, octylacrylamide / acrylate Methylmeth- / tert.Butylaminoethylmethacrylat / 2 Hydroxyproyl methacrylate copolymers, polyvinylpyrrolidone, vinylpyrrolidone / vinyl acetate copolymers, vinylpyrrolidone / dimethylaminoethyl methacrylate / vinyl caprolactam terpolymers and optionally derivatized cellulose ethers and silicones in question.

Suitable silicone compounds are, for example, dimethylpolysiloxanes, methylphenylpolysiloxanes, cyclic silicones and amino, fatty acid, alcohol, polyether, epoxy, fluorine, glycoside and / or alkyl-modified silicone compounds, which can be both liquid and resinous at room temperature. Simethicones, which are mixtures of dimethicones with an average chain length of 200 to 300 dimethylsiloxane units and hydrogenated silicates, are also suitable. A detailed overview of suitable volatile silicones can also be found by Todd et al. in Cosm.Toil. 91, 27 (1976). Typical examples of fats are glycerides, waxes include natural waxes such as candelilla wax, carnauba wax, Japanese wax, espresso grass wax, cork wax, guaruma wax, rice-germ oil wax, sugar cane wax, ouricury wax, montan wax, beeswax, shellac wax, walnut, lanolin ( Wool wax), pretzel fat, ceresin, ozokerite (earth wax), petrolatum, paraffin waxes, micro waxes; chemically modified waxes (hard waxes), such as montan ester waxes, Sasol waxes, hydrogenated jojoba waxes and synthetic waxes, such as polyalkylene waxes and polyethylene glycol waxes, are possible.

Metal salts of fatty acids, such as e.g. Magnesium, aluminum and / or zinc stearate or ricinoleate are used.

Biogenic active substances are, for example, tocopherol, tocopherol acetate, tocopherol palmitate, ascorbic acid, deoxyribonucleic acid, retinol, bisabolol, allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudo doceramides, essential oils, plant extracts and vitamin complexes.

Cosmetic deodorants counteract, mask or eliminate body odors. Body odors arise from the action of skin bacteria on apocrine sweat, whereby unpleasant smelling breakdown products are formed. Accordingly, deodorants contain active substances which act as germ-inhibiting agents, enzyme inhibitors, odor absorbers or odor maskers.

As a germ-inhibiting agent, which may be added to the cosmetics according to the invention, all substances which are effective against gram-positive bacteria are suitable, such as B. 4-hydroxybenzoic acid and its salts and esters, N- (4-chlorophenyl) -N ^' - (3,4 dichlorophenyl) urea, 2,4,4'-trichloro-2 ^' - hydroxydiphenyl ether (triclosan), 4-chloro-3,5-dimethylphenol, 2,2 ^' -methylene bis (6-bromo-4-chlorophenol), 3-methyl-4- (1-methylethyl) phenol, 2-benzyl 4-chlorophenol, 3- (4-chlorophenoxy) -1, 2-propanediol, 3-iodo-2-propynylbutylcarbamate, chlorhexidine, 3,4,4'-trichlorocarbanilide (TTC), antibacterial fragrances, thymol, thyme oil, eugenol , Clove oil, menthol, mint oil, farnesol, phenoxyethanol, glycerol monolaurate (GML), diglycerol monocaprinate (DMC), salicylic acid N-alkylamides such as. B. salicylic acid-n-octylamide or salicylic acid-n-decylamide.

Enzyme inhibitors can also be added to the cosmetics according to the invention. Suitable enzyme inhibitors are, for example, esterase inhibitors. These are preferably trialkyl such as trimethyl citrate, tripropyl, triisopropyl, tributyl citrate and especially triethyl citrate (Hydagen® ^® CAT, Fa. Cognis, Dusseldorf / FRG). The substances inhibit enzyme activity and thereby reduce odor. Other substances which can be considered as esterase inhibitors are sterol sulfates or phosphates, such as, for example, lanosterol, cholesterol, campesteric, stigmasterol and sitosterol sulfate or phosphate, dicarboxylic acids and their esters, such as, for example, glutaric acid, giutaric acid monoethyl ester, glutaric acid diethyl ester, adipic acid, Monoethyl adipate, diethyl adipate, malonic acid and diethyl malonate, hydroxycarboxylic acids and their esters such as, for example, citric acid, malic acid, tartaric acid or tartaric acid diethyl ester, and zinc glycinate.

Suitable odor absorbers are substances that absorb odor-forming compounds and can retain them to a large extent. They lower the partial pressure of the individual components and thus also reduce their speed of propagation. It is important that perfumes must remain unaffected. Odor absorbers are not effective against bacteria. They contain, for example, a complex zinc salt of ricinoleic acid as a main component or special, largely odorless fragrances that are known to the person skilled in the art "Fixateurs" are known, such as. B. extracts of Labdanum or Styrax or certain abietic acid derivatives.

Fragrance agents or perfume oils act as odor maskers and, in addition to their function as odor maskers, give the deodorants their respective fragrance.

Perfume oils include mixtures of natural and synthetic fragrances. Natural fragrances are extracts of flowers (lily, lavender, roses, jasmine, neroli, ylang-ylang), stems and leaves (geranium, patchouli, petitgrain), fruits (anise, coriander, caraway, juniper), fruit bowls (bergamot, Lemon, oranges), roots (mace, angelica, celery, cardamom, costus, iris, calmus), woods (pine, sandal, guaiac, cedar, rosewood), herbs and grasses (tarragon, lemongrass, sage, thyme ), Needles and twigs (spruce, fir, pine, mountain pine), resins and balsams (galbanum, elemi, benzoin, myrrh, olibanum, opoponax). Animal raw materials, such as civet and castoreum, are also suitable. Typical synthetic fragrance compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type. Fragrance compounds of the ester type are, for example, benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzylcarbinylacetate, phenylethyl acetate, linalyl benzoate, benzyl formate, ethyl methylphenyl glycinate, allyl cyclohexylalylpionyl xylpropylyl allyl propyl pylyl allyl propionate. The ethers include, for example, benzyl ethyl ether, the aldehydes include, for example, the linear alkanals with 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyclamaldehyde, hydroxycitronellal, lilial and bourgeonal, and the ketones include, for example, the ionones, o-isomethyl ionone and methyl cedryl ketone the alcohols anethole, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and terpineol, the hydrocarbons mainly include the terpenes and balsams. However, preference is given to using mixtures of different fragrances which together produce an appealing fragrance. Also etheric see oils of lower volatility, which are mostly used as aroma components, are suitable as perfume oils, for example sage oil, chamomile oil, clove oil, melissa oil, mint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, oliban oil, galbanum oil, labolanum oil and lavandin oil. Bergamot oil, dihydromyrcenol, lilial, lyral, citrohellol, phenylethyl alcohol, α-hexylcinnamaldehyde, geraniol, benzylacetone, cyclamenaldehyde, linalool, boi sambrene forte, ambroxan, indole, hedione, sandelice, lemon oil, mandarin allyl oil, orange allyl oil, orange glycol, are preferred , Lavandin oil, muscatel sage oil, ß-damascone, geranium oil bourbon, cyclohexyl salicylate, Vertofix Coeur, Iso-E-Super, Fixolide NP, evernyl, iraldein gamma, phenylacetic acid, geranyl acetate, benzyl acetate, rose oxide, romilllate, irotyl and floramate alone Mixtures used.

Antiperspirants (antiperspirants) reduce sweat formation by influencing the activity of the eccrine sweat glands and thus counteract armpit wetness and body odor. Aqueous or anhydrous formulations of antiperspirants typically contain the following ingredients:

(a) astringent active ingredients, (b) oil components,

(c) nonionic emulsifiers,

(d) co-emulsifiers,

(e) consistency generator,

(f) auxiliaries such. B. thickeners or complexing agents and / or (g) non-aqueous solvents such. As ethanol, propylene glycol and / or glycerin.

Salts of are particularly suitable as astringent antiperspirant active ingredients

Aluminum, zirconium or zinc. Such suitable antiperspirant active ingredients are, for example, aluminum chloride, aluminum chlorohydrate, aluminum dichlorohydrate, aluminum sesquichlorohydrate and their composite compounds z. B. with propylene glycol-1, 2nd Aluminum hydroxyallantoinate, aluminum chloride tartrate, aluminum zirconium trichlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium pentachlorohydrate and their complex compounds z. B. with amino acids such as glycine. In addition, conventional oil-soluble and water-soluble auxiliaries can be present in smaller amounts in antiperspirants. Examples of such oil-soluble auxiliaries are:

• anti-inflammatory, skin-protecting or fragrant essential oils,

• synthetic skin-protecting agents and / or

• oil-soluble perfume oils.

Common water-soluble additives are e.g. Preservatives, water-soluble fragrances, pH adjusters, e.g. Buffer mixtures, water soluble thickeners, e.g. water-soluble natural or synthetic polymers such as e.g. Xanthan gum, hydroxyethyl cellulose, polyvinyl pyrrolidone or high molecular weight polyethylene oxides.

Climbazole, octopirox and zinc pyrethione can be used as antidandruff agents.

Common film formers are, for example, chitosan, microcrystalline chitosan, quaternized chitosan, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymers, polymers of the acrylic acid series, quaternary cellulose derivatives, collagen, hyaluronic acid or its salts and similar compounds.

Montmorillonites, clay minerals, pemulene and alkyl-modified carbopol types (Goodrich) can serve as swelling agents for aqueous phases. Further suitable polymers or swelling agents can be found in the overview by R. Lochhead in Cosm.Toil. 108, 95 (1993). UV light protection factors are understood to mean, for example, organic substances (light protection filters) which are liquid or crystalline at room temperature and are able to absorb ultraviolet rays and release the absorbed energy in the form of longer-wave radiation, for example heat. UVB filters can be oil-soluble or water-soluble. Examples of oil-soluble substances are:

3-benzylidene camphor or 3-benzylidene norcampher and its derivatives, e.g. 3- (4-methylbenzylidene) camphor as described in EP 0693471 B1;

• 4-aminobenzoic acid derivatives, preferably 2-ethylhexyl 4-dimethylamino) benzoate, 2-octyl 4- (dimethylamino) benzoate and amyl 4- (dimethylamino) benzoate;

Esters of cinnamic acid, preferably 2-ethylhexyl 4-methoxycinnamate, propyl 4-methoxycinnamate, isoamyl 4-methoxycinnamate, 2-cyano-

2-ethylhexyl 3,3-phenylcinnamate (octocrylene);

• esters of salicylic acid, preferably salicylic acid 2-ethylhexyl ester, salicylic acid 4-isopropylbenzyl ester, salicylic acid homomethyl ester;

• Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;

• Esters of benzalmalonic acid, preferably di-2-ethylhexyl 4-methoxybenzmalonate;

Triazine derivatives, e.g. 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1, 3,5-triazine and octyl triazone, as described in EP 0818450 A1 or dioctyl butamido triazone (Uvasorb® HEB );

Propane-1,3-dione, e.g. 1- (4-tert-butylphenyl) -3-4'methoxyphenyl) propane-1,3-dione;

• Ketotricyclo (5.2.1.0) decane derivatives, as described in EP 0694521 B1.

Possible water-soluble substances are: • 2-phenylbenzimidazole-5-sulfonic acid and its alkali, alkaline earth, ammonium, alkylammonium, alkanolammonium and glucammonium salts;

• Sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;

Sulfonic acid derivatives of 3-benzylidene camphor, e.g. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid and 2-methyl-5- (2-oxo-3-bornylidene) sulfonic acid and their salts.

Derivatives of benzoylmethane, such as 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione, 4-tert, are particularly suitable as typical UV-A filters. -Butyl-4'-methoxydibenzoylmethane (Parsol 1789), 1-phenyl-3- (4'-isopropylphenyl) -propane-1, 3-dione and enamine compounds as described in DE 19712033 A1 (BASF). The UV-A and UV-B filters can of course also be used in mixtures. In addition to the soluble substances mentioned, insoluble light protection pigments, namely finely dispersed metal oxides or salts, are also suitable for this purpose. Examples of suitable metal oxides are, in particular, zinc oxide and titanium dioxide and, in addition, oxides of iron, zirconium, silicon, manganese, aluminum and cerium and mixtures thereof. Silicates (talc), barium sulfate or zinc stearate can be used as salts. The oxides and salts are used in the form of the pigments for skin-care and skin-protecting emulsions and decorative cosmetics. The particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm. They can have a spherical shape, but it is also possible to use particles which have an ellipsoidal shape or a shape which differs from the spherical shape in some other way. The pigments can also be surface-treated, ie hydrophilized or hydrophobicized. Typical examples are coated titanium dioxides, such as titanium dioxide T 805 (Degussa) or Eusoiex® T2000 (Merck). The main hydrophobic coating agents used are silicones and especially trialkoxy octylsilane or Simethicone in question. So-called micro- or nanopigments are preferably used in sunscreens. Micronized zinc oxide is preferably used. Further suitable UV light protection filters can be found in the overview by P.Finkel in SÖFW-Journal 122, 543 (1996).

In addition to the two aforementioned groups of primary light stabilizers, secondary light stabilizers of the antioxidant type can also be used, which interrupt the photochemical reaction chain which is triggered when UV radiation penetrates the skin. Typical examples are amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine) , Carotenoids, carotenes (eg α-carotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and their derivatives, lipoic acid and their derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, Cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters ) as well as their salts, dilaurylthiodipropionate, distearylthiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g. butioninsulfoximines, homocysteine sulfoximine, butioninsulfones, penta-, hexa-, hepa-, hepa- tathioninsulfoximin) in very g achieve tolerable dosages (e.g. pmol to μmol / kg), also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin , Biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g. γ-linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) as well as coniferyl benzoate of benzoin, rutinic acid and its derivatives, α- Rutin, ferulic acid, Furfurylidenglucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, Nordihydroguajakharzsäure, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and derivatives thereof, mannose and derivatives thereof, superoxide dismutase, zinc and derivatives thereof (for example ZnO, ZnS0 _4), selenium and derivatives thereof (for example selenium Methionine), stilbenes and their derivatives (for example stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances.

Hydrotropes such as ethanol, isopropyl alcohol or polyols can also be used to improve the flow behavior. Polyols that come into consideration here preferably have 2 to 15 carbon atoms and at least two hydroxyl groups. The polyols can also contain further functional groups, in particular amino groups, or be modified with nitrogen. Typical examples are

• glycerin;

Alkylene glycols, such as, for example, ethylene glycol, diethylene glycol, propylene glycol, butylene glycol, hexylene glycol and polyethylene glycols with an average molecular weight of 100 to 1,000 daltons;

Technical oligoglycerol mixtures with a degree of self-condensation of 1.5 to 10, such as technical diglycerol mixtures with a diglycerol content of 40 to 50% by weight;

• Methyl compounds such as, in particular, trimethylolethane, trimethylolpropane, trimethylolbutane, pentaerythritol and dipentaerythritol;

• Lower alkyl glucosides, in particular those with 1 to 8 carbons in the alkyl radical, such as methyl and butyl glucoside;

• Sugar alcohols with 5 to 12 carbon atoms, such as, for example, sorbitol or mannitol, • Sugar with 5 to 12 carbon atoms, such as, for example, glucose or sucrose; Aminosugars, such as glucamine;

• Dialcohol amines, such as diethanolamine or 2-amino-1, 3-propanediol.

Suitable preservatives are, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid and the other classes of substances listed in Appendix 6, Parts A and B of the Cosmetics Ordinance. N, N-diethyl-m-toluamide, 1, 2-pentanediol or ethyl butylacetylaminopropionate are suitable as insect repellents, and dihydroxyacetone is suitable as a self-tanning agent.

The dyes which can be used are the substances which are suitable and approved for cosmetic purposes, as compiled, for example, in the publication "Cosmetic Dyes" by the Dye Commission of the German Research Foundation, Verlag Chemie, Weinheim, 1984, pp. 81-106. These dyes are usually used in concentrations of 0.001 to 0.1% by weight, based on the mixture as a whole.

The total proportion of auxiliaries and additives can be 1 to 50, preferably 5 to 40,% by weight, based on the composition. The agents can be produced by customary cold or hot processes; the phase inversion temperature method is preferably used.

Claims

claims

1. Use of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia for the prophylactic and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals.

2. Use according to claim 1, characterized in that the undesirable physical or mental conditions to be treated are selected from somatic, psychosomatic and psychological disorders in humans or animals.

3. Use according to claim 1 or 2, characterized in that the undesirable physical conditions to be treated are selected from

Inflammatory processes, in particular among inflammatory processes, which are caused by increased leukotriene formation.

4. Use according to one of the preceding claims, characterized in that the conditions to be treated are selected from inflammatory joint diseases, epidermal lesions (psoriasis), allergic and chronic asthma, endotoxin shock, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or chronic hepatitis ,

5. Use according to claim 1 or 2, characterized in that the undesirable physical conditions to be treated are caused by increased leukocyte elastase or piasmin activity or that the undesirable physical conditions to be treated can be treated by inhibiting normal leukocyte elastase or piasmin activity.

6. Use according to claim 5, characterized in that the conditions to be treated are selected from emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatic arthritis, which are caused by increased leukocyte elastase activity, and tumor activity and tumor metastases caused by increased piasmin activity.

7. Use according to one of the preceding claims, characterized in that the use is carried out intraperitoneally, orally, buccally, rectally, intramuscularly, topically, subcutaneously, by inhalation, intra-articularly or intravenously.

8. Use according to claim 7, characterized in that the use is in the form of tablets, dragees, capsules, solutions, emulsions, ointments, creams, inhalation preparations, aerosols or suppositories.

9. Use of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia for the manufacture of a medicament for the prophylactic and / or therapeutic treatment of undesirable physical or mental conditions in humans or animals, in particular for the treatment of the states mentioned in claims 2 to 6.

10. Use according to claim 9, characterized in that the use takes place together with other chemically pure medicinal substances and / or herbal medicinal products.

11. Use of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia in or for the production of hand washing detergents, hand dishwashing detergents, cosmetics or personal care products.

12. Dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia.

13. A process for the preparation of dihydroboswellic acids, their physiologically acceptable salts, derivatives, salts of the derivatives or hydrogenated extracts from Boswellia, wherein a. Boswellia resin or Boswellic acids (one or different) or physiologically acceptable salts, derivatives or salts of the derivatives of these acids in a suitable solvent and b. the dissolved resin or the dissolved acids, salts, derivatives or salts of the derivatives are hydrogenated in the presence of a hydrogenation catalyst.